GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Gross Property, Plant and Equipment

Zai Lab (Zai Lab) Gross Property, Plant and Equipment : $98.8 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Zai Lab Gross Property, Plant and Equipment?

Zai Lab's quarterly gross PPE declined from Jun. 2023 ($101.2 Mil) to Sep. 2023 ($99.4 Mil) and declined from Sep. 2023 ($99.4 Mil) to Dec. 2023 ($98.8 Mil).

Zai Lab's annual gross PPE increased from Dec. 2021 ($74.7 Mil) to Dec. 2022 ($100.8 Mil) but then declined from Dec. 2022 ($100.8 Mil) to Dec. 2023 ($98.8 Mil).


Zai Lab Gross Property, Plant and Equipment Historical Data

The historical data trend for Zai Lab's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Gross Property, Plant and Equipment Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only 42.33 57.39 74.71 100.84 98.83

Zai Lab Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.84 104.66 101.23 99.41 98.83

Zai Lab Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Zai Lab  (NAS:ZLAB) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Zai Lab Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Zai Lab's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab (Zai Lab) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Gross Property, Plant and Equipment
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Harald Reinhart officer: Chief Medical Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Edmondson Frazor Titus Iii officer: Chief Legal Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Ying Du director, officer: Chairwoman & CEO C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Rafael Amado officer: See Remarks 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Joshua L Smiley officer: Chief Operating Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen officer: Chief Financial Officer 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth director 37 HANCOCK STREET, BOSTON MA 02114
John D Diekman director C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Tao Fu director, officer: President & COO 3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul officer: Chief Financial Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen director 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210